Pharming Group N.V.

Pharming Group N.V. (PINKSHEETS: PHGUF) Leiden, The Netherlands, July 14, 2008. Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today that its wholly owned subsidiary DNage is participating in a large European study, called MARK-AGE, to identify and establish biomarkers of human ageing. Under the Seventh Research Framework Programme (FP7), the European Union has allocated a total budget of almost € 12 million for this study for a period of five years.

Pharming Group N.V. (PINKSHEETS: PHGUF) Leiden, The Netherlands, July 11, 2008. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today positive results from ongoing open-label studies with recombinant human C1 inhibitor (Rhucin®) for the treatment of acute attacks of Hereditary Angioedema (HAE).

Pharming Group N.V. (PINKSHEETS: PHGUF) Important step for recombinant fibrinogen and biomaterials program

Pharming Group N.V. (PINKSHEETS: PHGUF) Company to move forward with regulatory filings